Biogenesis and function of endogenous and exogenous siRNAs

Wiley Interdisciplinary Reviews: RNA

Volumn 1, Issue 1, 2010, Pages 117-131

  Snead, Nicholas M ^a   Rossi, John J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGONAUTE 2 PROTEIN; DICER; LOCKED NUCLEIC ACID; MICRORNA; PARVOVIRUS VECTOR; RNA POLYMERASE II; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SMALL UNTRANSLATED RNA; MESSENGER RNA;

3' UNTRANSLATED REGION; BIOGENESIS; CAENORHABDITIS ELEGANS; COMBINATORIAL CHEMISTRY; DROSOPHILA; GENE REPRESSION; HYPERCHOLESTEROLEMIA; NONHUMAN; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; REVIEW; RNA CLEAVAGE; RNA DEGRADATION; RNA INTERFERENCE; RNA SEQUENCE; RNA SYNTHESIS; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84857777210     PISSN: 17577004     EISSN: 17577012     Source Type: Journal    
DOI: 10.1002/wrna.14     Document Type: Review

References (140)

1. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990, 2: 279-289.
2. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391: 806-811.
3. Zeng Y, Cullen BR. RNA interference in human cells is restricted to the cytoplasm. RNA 2002, 8: 855-860.
4. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411: 494-498.
5. Tam OH, Aravin AA, Stein P, Girard A, Murchison EP, et al. Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes. Nature 2008, 453: 534-538.
6. Watanabe T, Totoki Y, Toyoda A, Kaneda M, Kuramochi-Miyagawa S, et al. Endogenous siRNAs from naturally formed dsRNAs regulate transcripts in mouse oocytes. Nature 2008, 453: 539-543.
7. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001, 294: 853-858.
8. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001, 294: 858-862.
9. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001, 294: 862-864.
10. Lee Y, Kim M, Han J, Yeom KH, Lee S, et al. microRNA genes are transcribed by RNA polymerase II. EMBO J 2004, 23: 4051-4060.
11. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006, 13: 1097-1101.
12. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006, 34: D140-D144. (Database issue).
13. Han J, Lee Y, Yeom KH, Nam JW, Heo I, et al. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell 2006, 125: 887-901.
14. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, et al. The Microprocessor complex mediates the genesis of microRNAs. Nature 2004, 432: 235-240.
15. Yeom KH, Lee Y, Han J, Suh MR, Kim VN. Characterization of DGCR8/Pasha, the essential cofactor for Drosha in primary miRNA processing. Nucleic Acids Res 2006, 34: 4622-4629.
16. Zeng Y, Cullen BR. Sequence requirements for microRNA processing and function in human cells. RNA 2003, 9: 112-123.
17. Zeng Y, Cullen BR. Efficient processing of primary microRNA hairpins by Drosha requires flanking nonstructured RNA sequences. J Biol Chem 2005, 280: 27595-27603.
18. Zeng Y, Yi R, Cullen BR. Recognition and cleavage of primary microRNA precursors by the nuclear processing enzyme Drosha. EMBO J 2005, 24: 138-148.
19. Trabucchi M, Briata P, Garcia-Mayoral M, Haase AD, Filipowicz W, et al. The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs. Nature 2009, 459: 1010-1014.
20. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003, 17: 3011-3016.
21. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004, 10: 185-191.
22. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science 2004, 303: 95-98.
23. Castanotto D, Lingeman R, Riggs AD, Rossi JJ. CRM1 mediates nuclear-cytoplasmic shuttling of mature microRNAs. Proc Natl Acad Sci USA 2009, 106: 21655-21659.
24. Stade K, Ford CS, Guthrie C, Weis K. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 1997, 90: 1041-1050.
25. Zhang H, Kolb FA, Jaskiewicz L, Westhof E, Filipowicz W. Single processing center models for human Dicer and bacterial RNase III. Cell 2004, 118: 57-68.
26. Macrae IJ, Li F, Zhou K, Cande WZ, Doudna JA. Structure of Dicer and mechanistic implications for RNAi. Cold Spring Harb Symp Quant Biol 2006, 71: 73-80.
27. Soifer HS, Sano M, Sakurai K, Chomchan P, Saetrom P, et al. A role for the Dicer helicase domain in the processing of thermodynamically unstable hairpin RNAs. Nucleic Acids Res 2008, 36: 6511-6522.
28. Zhang H, Kolb FA, Brondani V, Billy E, Filipowicz W. Human Dicer preferentially cleaves dsRNAs at their termini without a requirement for ATP. EMBO J 2002, 21: 5875-5885.
29. Ma E, MacRae IJ, Kirsch JF, Doudna JA. Autoinhibition of human dicer by its internal helicase domain. J Mol Biol 2008, 380: 237-243.
30. Provost P, Dishart D, Doucet J, Frendewey D, Samuelsson B, et al. Ribonuclease activity and RNA binding of recombinant human Dicer. EMBO J 2002, 21: 5864-5874.
31. Daniels SM, Melendez-Pena CE, Scarborough RJ, Daher A, Christensen HS, et al. Characterization of the TRBP domain required for dicer interaction and function in RNA interference. BMC Mol Biol 2009, 10: 38.
32. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005, 436: 740-744.
33. Saunders LR, Barber GN. The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB J 2003, 17: 961-983.
34. Laraki G, Clerzius G, Daher A, Melendez-Pena C, Daniels S, et al. Interactions between the double-stranded RNA-binding proteins TRBP and PACT define the Medipal domain that mediates protein-protein interactions. RNA Biol 2008, 5: 92-103.
35. Paroo Z, Ye X, Chen S, Liu Q. Phosphorylation of the human microRNA-generating complex mediates MAPK/Erk signaling. Cell 2009, 139: 112-122.
36. Castanotto D, Sakurai K, Lingeman R, Li H, Shively L, et al. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res 2007, 35: 5154-5164.
37. Parker GS, Maity TS, Bass BL. dsRNA binding properties of RDE-4 and TRBP reflect their distinct roles in RNAi. J Mol Biol 2008, 384: 967-979.
38. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003, 115: 199-208.
39. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs Exhibit Strand Bias. Cell 2003, 115: 209-216.
40. Tomari Y, Matranga C, Haley B, Martinez N, Zamore PD. A protein sensor for siRNA asymmetry. Science 2004, 306: 1377-1380.
41. Gredell JA, Dittmer MJ, Wu M, Chan C, Walton SP. Recognition of siRNA asymmetry by TAR RNA binding protein. Biochemistry 2010, 49: 3148-3155.
42. Tomari Y, Du T, Haley B, Schwarz DS, Bennett R, et al. RISC assembly defects in the Drosophila RNAi mutant armitage. Cell 2004, 116: 831-841.
43. Tahbaz N, Kolb FA, Zhang H, Jaronczyk K, Filipowicz W, et al. Characterization of the interactions between mammalian PAZ PIWI domain proteins and Dicer. EMBO Rep 2004, 5: 189-194.
44. Lee YS, Nakahara K, Pham JW, Kim K, He Z, et al. Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. Cell 2004, 117: 69-81.
45. Haase AD, Jaskiewicz L, Zhang H, Laine S, Sack R, et al. TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing. EMBO Rep 2005, 6: 961-967.
46. MacRae IJ, Ma E, Zhou M, Robinson CV, Doudna JA. In vitro reconstitution of the human RISC-loading complex. Proc Natl Acad Sci USA 2008, 105: 512-517.
47. Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002, 110: 563-574.
48. Wang HW, Noland C, Siridechadilok B, Taylor DW, Ma E, et al. Structural insights into RNA processing by the human RISC-loading complex. Nat Struct Mol Biol 2009, 16: 1148-1153.
49. Kim K, Lee YS, Carthew RW. Conversion of pre-RISC to holo-RISC by Ago2 during assembly of RNAi complexes. RNA 2007, 13: 22-29.
50. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 2005, 123: 607-620.
51. Robb GB, Rana TM. RNA helicase A interacts with RISC in human cells and functions in RISC loading. Mol Cell 2007, 26: 523-537.
52. Chu CY, Rana TM. Translation repression in human cells by microRNA-induced gene silencing requires RCK/p54. PLoS Biol 2006, 4: 1122-1136.
53. Minshall N, Kress M, Weil D, Standart N. Role of p54 RNA helicase activity and its C-terminal domain in translational repression, P-body localization and assembly. Mol Biol Cell 2009, 20: 2464-2472.
54. Takimoto K, Wakiyama M, Yokoyama S. Mammalian GW182 contains multiple Argonaute-binding sites and functions in microRNA-mediated translational repression. RNA 2009, 15: 1078-1089.
55. Ishizuka A, Siomi MC, Siomi H. A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins. Genes Dev 2002, 16: 2497-2508.
56. Jin P, Alisch RS, Warren ST. RNA and microRNAs in fragile X mental retardation. Nat Cell Biol 2004, 6: 1048-1053.
57. Jin P, Zarnescu DC, Ceman S, Nakamoto M, Mowrey J, et al. Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci 2004, 7: 113-117.
58. Plante I, Davidovic L, Ouellet DL, Gobeil LA, Tremblay S, et al. Dicer-Derived MicroRNAs Are Utilized by the Fragile X Mental Retardation Protein for Assembly on Target RNAs. J Biomed Biotechnol 2006, 2006: 64347.
59. Zekri L, Huntzinger E, Heimstadt S, Izaurralde E. The silencing domain of GW182 interacts with PABPC1 to promote translational repression and degradation of microRNA targets and is required for target release. Mol Cell Biol 2009, 29: 6220-6231.
60. Liu Y, Ye X, Jiang F, Liang C, Chen D, et al. C3PO, an endoribonuclease that promotes RNAi by facilitating RISC activation. Science 2009, 325: 750-753.
61. Duursma AM, Kedde M, Schrier M, le Sage C, Agami R. miR-148 targets human DNMT3b protein coding region. RNA 2008, 14: 872-877.
62. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116: 281-297.
63. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004, 305: 1437-1441.
64. Rivas FV, Tolia NH, Song JJ, Aragon JP, Liu J, et al. Purified Argonaute2 and an siRNA form recombinant human RISC. Nat Struct Mol Biol 2005, 12: 340-349.
65. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001, 20: 6877-6888.
66. Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science 2004, 304: 594-596.
67. Wang B, Li S, Qi HH, Chowdhury D, Shi Y, et al. Distinct passenger strand and mRNA cleavage activities of human Argonaute proteins. Nat Struct Mol Biol 2009, 16: 1259-1266.
68. Gibbings DJ, Ciaudo C, Erhardt M, Voinnet O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat Cell Biol 2009, 11: 1143-1149.
69. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 2007, 17: 118-126.
70. Fabian MR, Mathonnet G, Sundermeier T, Mathys H, Zipprich JT, et al. Mammalian miRNA RISC recruits CAF1 and PABP to affect PABP-dependent deadenylation. Mol Cell 2009, 35: 868-880.
71. Parker R, Song H. The enzymes and control of eukaryotic mRNA turnover. Nat Struct Mol Biol 2004, 11: 121-127.
72. Eulalio A, Behm-Ansmant I, Schweizer D, Izaurralde E. P-body formation is a consequence, not the cause, of RNA-mediated gene silencing. Mol Cell Biol 2007, 27: 3970-3981.
73. Mathonnet G, Fabian MR, Svitkin YV, Parsyan A, Huck L, et al. microRNA inhibition of translation initiation in vitro by targeting the cap-binding complex eIF4F. Science 2007, 317: 1764-1767.
74. Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 2005, 309: 1573-1576.
75. Wang B, Yanez A, Novina CD. microRNA-repressed mRNAs contain 40S but not 60S components. Proc Natl Acad Sci USA 2008, 105: 5343-5348.
76. Chen CY, Zheng D, Xia Z, Shyu AB. Ago-TNRC6 triggers microRNA-mediated decay by promoting two deadenylation steps. Nat Struct Mol Biol 2009, 16: 1160-1166.
77. Beilharz TH, Humphreys DT, Clancy JL, Thermann R, Martin DI, et al. microRNA-mediated messenger RNA deadenylation contributes to translational repression in mammalian cells. PLoS ONE 2009, 4: 1-12.
78. ' untranslated region in mammalian mRNAs. Nat Struct Mol Biol 2009, 16: 144-150.
79. Petersen CP, Bordeleau ME, Pelletier J, Sharp PA. Short RNAs repress translation after initiation in mammalian cells. Mol Cell 2006, 21: 533-542.
80. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120: 15-20.
81. Zeng Y, Cai X, Cullen BR. Use of RNA polymerase II to transcribe artificial microRNAs. Methods Enzymol 2005, 392: 371-380.
82. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 2008, 105: 5868-5873.
83. Boden D, Pusch O, Silbermann R, Lee F, Tucker L, et al. Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res 2004, 32: 1154-1158.
84. Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 2002, 9: 1327-1333.
85. Czauderna F, Fechtner M, Dames S, Aygun H, Klippel A, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003, 31: 2705-2716.
86. Kim DH, Longo M, Han Y, Lundberg P, Cantin E, et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 2004, 22: 321-325.
87. Schwarz DS, Hutvagner G, Haley B, Zamore PD. Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol Cell 2002, 10: 537-548.
88. Murchison EP, Partridge JF, Tam OH, Cheloufi S, Hannon GJ. Characterization of Dicer-deficient murine embryonic stem cells. Proc Natl Acad Sci USA 2005, 102: 12135-12140.
89. Salomon W, Bulock K, Lapierre J, Pavco P, Woolf T, et al. Modified dsRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC. Nucleic Acids Res 2010 DOI:10.1093/nar/gkq055.
90. Bramsen JB, Laursen MB, Nielsen AF, Hansen TB, Bus C, et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res 2009, 37: 2867-2881.
91. Lima WF, Wu H, Nichols JG, Sun H, Murray HM, et al. Binding and cleavage specificities of human Argonaute2. J Biol Chem 2009, 284: 26017-26028.
92. Vickers TA, Lima WF, Wu H, Nichols JG, Linsley PS, et al. Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 'Slicer' independent and can be mediated by Ago1. Nucleic Acids Res 2009, 37: 6927-6941.
93. Sano M, Sierant M, Miyagishi M, Nakanishi M, Takagi Y, et al. Effect of asymmetric terminal structures of short RNA duplexes on the RNA interference activity and strand selection. Nucleic Acids Res 2008, 36: 5812-5821.
94. Sun X, Rogoff HA, Li CJ. Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat Biotechnol 2008, 26: 1379-1382.
95. Chang CI, Yoo JW, Hong SW, Lee SE, Kang HS, et al. Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol Ther 2009, 17: 725-732.
96. Bramsen JB, Laursen MB, Damgaard CK, Lena SW, Babu BR, et al. Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res 2007, 35: 5886-5897.
97. Chu CY, Rana TM. Potent RNAi by short RNA triggers. RNA 2008, 14: 1714-1719.
98. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006, 12: 1197-1205.
99. '-O-methyl-modified RNAs act as TLR7 antagonists. Mol Tther 2007, 15: 1663-1669.
100. Layzer JM, McCaffrey AP, Tanner AK, Huang ZAN, Kay MA, et al. In vivo activity of nuclease-resistant siRNAs. RNA 2004, 10: 766-771.
101. Bartlett DW, Davis ME. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol Bioeng 2007, 97: 909-921.
102. Carlucci M, Kierzek E, Olejnik A, Turner DH, Kierzek R. Chemical synthesis of LNA-2-thiouridine and its influence on stability and selectivity of oligonucleotide binding to RNA. Biochemistry 2009, 48: 10882-10893.
103. Mook OR, Baas F, de Wissel MB, Fluiter K. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther 2007, 6: 833-843.
104. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005, 23: 222-226.
105. Rose SD, Kim DH, Amarzguioui M, Heidel JD, Collingwood MA, et al. Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res 2005, 33: 4140-4156.
106. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005, 123: 631-640.
107. Dore-Savard L, Roussy G, Dansereau MA, Collingwood MA, Lennox KA, et al. Central delivery of Dicer-substrate siRNA: a direct application for pain research. Mol Ther 2008, 16: 1331-1339.
108. Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B, et al. Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 2009, 17: 162-168.
109. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009, 27: 925-932.
110. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, et al. Rational siRNA design for RNA interference. Nat Biotechnol 2004, 22: 326-330.
111. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009, 119: 661-673.
112. Robbins M, Judge A, Ambegia E, Choi C, Yaworski E, et al. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 2008, 19: 991-999.
113. '-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther 2007, 15: 1663-1669.
114. Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides 2009, 19: 89-102.
115. Robbins MA, Rossi JJ. Sensing the danger in RNA. Natl Med 2005, 11: 250-251.
116. Kariko K, Bhuyan P, Capodici J, Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol 2004, 172: 6545-6549.
117. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008, 452: 591-597.
118. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003, 5: 834-839.
119. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006, 2: 711-719.
120. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007, 6: 443-453.
121. Dykxhoorn DM, Lieberman J. The Silent Revolution: RNA Interference as Basic Biology, Research Tool, and Therapeutic. Annu Rev Med 2005, 56: 401-423. DOI:10.1146/annurev.med.56.082103.104606.
122. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007, 8: 173-184.
123. De Paula D, Bentley MV, Mahato RI. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 2007, 13: 431-456.
124. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005, 23: 457-462.
125. '-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Natl Med 2008, 14: 1256-1263.
126. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006, 441: 537-541.
127. John M, Constien R, Akinc A, Goldberg M, Moon YA, et al. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 2007, 449: 745-747.
128. Calin GA, Croce CM. microRNA signatures in human cancers. Nat Rev Cancer 2006, 6: 857-866.
129. Calin GA, Croce CM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 2006, 25: 6202-6210.
130. Calin GA, Croce CM. microRNA-cancer connection: the beginning of a new tale. Cancer Res 2006, 66: 7390-7394.
131. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005, 122: 6-7.
132. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Biomed Eng 2009, 60: 167-179.
133. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137: 1005-1017.
134. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452: 896-899.
135. Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 2009, 27: 839-849.
136. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006, 103: 6315-6320.
137. Guo S, Tschammer N, Mohammed S, Guo P. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum Gene Ther 2005, 16: 1097-1110.
138. McNamara JO, Andrechek ER, Wang Y, Viles KD, Rempel RE, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006, 24: 1005-1015.
139. Zhou J, Li H, Li S, Zaia J, Rossi JJ. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 2008, 16: 1481-1489.
140. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346: 818-822.